Liselotte Sabroe | Afp | Getty Pictures
Novo Nordisk, Europe’s premier firm by market capitalization, on Wednesday noted improved-than-expected 2023 earnings, as sales of its wildly common anti-weight problems and diabetic issues prescription drugs ongoing to soar.
The maker of excess weight decline drug Wegovy and diabetic issues drug Ozempic reported an enhance in gross sales of 31% in Danish kroner and 36% at regular exchange costs (CER) to 232.3 billion kroner ($33.71 billion).
Entire-yr running gain jumped by 37% in kroner and 44% at consistent trade rates to 102.6 billion kroner.
The Danish pharmaceutical big mentioned it expects product sales growth this yr of among 18% and 26% in CER terms, as need surges for Wegovy and Ozempic, which include the identical energetic component.
The 2023 effects were fueled by sturdy efficiency in the company’s diabetic issues and being overweight care division, with obesity treatment in individual spiking by 154% at CER to 41.6 billion.
“The unmet requirements in kind 2 diabetes and being overweight are developing by the working day, and the mounting prevalence of these carefully relevant threats to international wellbeing has developed surging demand from customers for our GLP-1-based therapies,” Chairman Helge Lund and CEO Lars Fruergaard Jørgensen stated in the earnings report.
“This has enabled us to get to extra individuals than at any level in our 100-yr background, contributing to robust profits development throughout North America and Worldwide Functions.”
The company also acknowledged that this had resulted in elevated tension on its provide chain, top to “periodic constraints” across its portfolio as it struggled to continue to keep rate with demand from customers in 2023.
“We have responded by investing heavily in growing our output capacity with the intention of serving thousands and thousands much more sufferers all over the world. In 2023 on your own, we announced investments totalling extra than DKK 75 billion in the enlargement of our manufacturing web-sites throughout the world,” the chairman and CEO said.
“With building now underway on these jobs, we try to run our present facilities 24 hrs a day, 7 times a 7 days, as we make extra of our everyday living-changing medicines than at any time ahead of.”
